CHAMPIONS ONCOLOGY, INC. Impairment of Long-Lived Assets Held-for-use
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-07-27
- CHAMPIONS ONCOLOGY, INC. impairment of long-lived assets held-for-use for fiscal 2026 was $0.00.
- CHAMPIONS ONCOLOGY, INC. impairment of long-lived assets held-for-use for fiscal 2025 was $0.00.
- CHAMPIONS ONCOLOGY, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $807.00K.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2026-04-30 | $0.00 10-K · filed 2026-07-27 |
| 2025-04-30 | $0.00 10-K · filed 2026-07-27 |
| 2024-04-30 | $0.00 10-K · filed 2025-07-23 |
| 2023-04-30 | $807.00K 10-K · filed 2024-07-19 |
| 2022-04-30 | $0.00 10-K · filed 2023-07-24 |
| 2021-04-30 | $0.00 10-K · filed 2022-07-22 |
| 2020-04-30 | $0.00 10-K · filed 2021-07-26 |
| 2019-04-30 | $0.00 10-K · filed 2020-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |